Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Impinj Inc (PI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Impinj Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.76 (market cap $4.49B), while Impinj Inc trades at $140.94 (market cap $4.20B). The key difference: ACADIA Pharmaceuticals Inc. and Impinj Inc are close in size by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Impinj Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | PI | |
|---|---|---|
Market Cap | $4.49B | $4.20B |
Sector | Health | Technology |
52-Week High | $28.06 | $241.91 |
52-Week Low | $20.06 | $91.34 |
Enterprise Value | $3.69B | $4.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Impinj (PI) trades at $148.00, up 4.53% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $167.50. Recent Q1 2026 earnings beat expectations, but the company shows negative net income margins and elevated valuation multiples. Key news includes upcoming Q2 2026 results and insider selling activity.
The stock offers upside potential from strong analyst buy ratings and RFID technology leadership, but risks include persistent profitability challenges, high debt-to-asset ratio (51.52% in 2025), and sensitivity to earnings misses. Investor sentiment is mixed amid growth execution concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →
